Cart
sales@molnova.com
PI3K inhibitor X
CAS No. 956958-53-5
PI3K inhibitor X ( XL-147 analog )
Catalog No. M16833 CAS No. 956958-53-5
PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 29 | Get Quote |
|
| 5MG | 45 | Get Quote |
|
| 10MG | 72 | Get Quote |
|
| 25MG | 128 | Get Quote |
|
| 50MG | 205 | Get Quote |
|
| 100MG | 354 | Get Quote |
|
| 200MG | 460 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePI3K inhibitor X
-
NoteResearch use only, not for human use.
-
Brief DescriptionPI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.
-
DescriptionPI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor of class I PI3Ks with IC50 of 39, 36, 23 and 383 nM for p110α, δ, γ and β respectively; Compound 147 in patent WO2012006552A1.
-
SynonymsXL-147 analog
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorDNA-PK;PI3Kα;PI3Kβ;PI3Kγ;PI3Kδ
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number956958-53-5
-
Formula Weight448.52
-
Molecular FormulaC21H16N6O2S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(C)C=C1)(NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4)=O
-
Chemical NameBenzenesulfonamide, N-[3-(2,1,3-benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Carlos L. Arteaga, et al. Combinations of kinase inhibitors for the treatment of cancer. WO 2012006552 A1.
molnova catalog
related products
-
ETP-46321
ETP-46321 is a potent, selective, orally bioavailable dual PI3K α/δ inhibitor with IC50 of 2.3/14.2 nM.
-
GSK-2636771
GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.
-
Idelalisib
Idelalisib is a selective inhibitor of p110δ(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
